Assessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause

Simply Wall St.04-09

Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626390888?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137","is_english":true,"pubTime":"2026-04-09 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626390888","market":"nz","top_or_hot":-1,"title":"Assessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause","media":"Simply Wall St.","content":"<div>\n<p>Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/assessing-pfizer-pfe-valuation-after-bearish-analyst-rating\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 11:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/assessing-pfizer-pfe-valuation-after-bearish-analyst-rating><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/assessing-pfizer-pfe-valuation-after-bearish-analyst-rating\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BBT3K403.USD","symbol_name":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/assessing-pfizer-pfe-valuation-after-bearish-analyst-rating","article_id":"2626390888","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/assessing-pfizer-pfe-valuation-after-bearish-analyst-rating","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626390888","pubTimestamp":1775705778,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-19 vaccine trial adds to short term uncertainty.\nSee our latest analysis for Pfizer.\nDespite the latest bearish commentary and trial pause weighing on sentiment in recent days, Pfizer’s share price shows a 9.1% year to date share price return and a 31.0% total shareholder return over the past...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4592":"伊斯兰概念","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4550":"红杉资本持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4007":"制药","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4581":"高盛持仓","SG9999002232.USD":"Allianz Global High Payout USD","BK4599":"减肥药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4585":"ETF&股票定投概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK7095":"多种金属与采矿","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","PFE":"辉瑞","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H"},"translate_title":"在分析师评级看跌和新冠疫苗试验暂停后评估辉瑞(PFE)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98},"content_text":"Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-19 vaccine trial adds to short term uncertainty. See our latest analysis for Pfizer. Despite the latest bearish commentary and trial pause weighing on sentiment in recent days, Pfizer’s share price shows a 9.1% year to date share price return and a 31.0% total shareholder return over the past year. This suggests recent momentum has been improving from a weaker multi year total return profile. If this mix of headline risk and recovery has you thinking about where else capital could work, it may be worth scanning for other healthcare names using our screener for 34 healthcare AI stocks With Pfizer trading at $27.47, sitting close to a modest 4% discount to the average analyst price target yet showing a 56.9% intrinsic discount, the key question is whether the stock offers genuine value or whether the market already reflects future growth. AdvertisementMost Popular Narrative: 10.3% Undervalued Pfizer's most followed narrative pegs fair value at $30.62 versus the recent $27.47 share price. According to that framework, this implies meaningful upside.  I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines. This should keep revenue flat, possibly growing in low to mid single digits in an optimistic scenario. Also, I think they will continue to release many new products that are already in phase 3 of research. If they're able to do this, maintain a 70% operational margin, increase profitability (by cutting costs, expanding margins etc.) and paying down debt, in the long term i see good anual returns (low double digits) from current stock price levels. There is risk for investors in the meantime! Pfizers transition needs to happen fast otherwise Pfizer will have to borrow more money due to the capital nature of the bussiness. Of course, this is not a capital light industry and pfizer debt levels are allready very high when we compare them with free cash flow to equity. Also, there is a risk of a dividend cut wich would harm investors. Investors should be aware of these risks in this turnaround play.  Read the complete narrative. This narrative leans heavily on oncology gains, new phase 3 launches and high profitability assumptions to justify the gap to $30.62. It would be useful to understand which specific growth, margin and discount rate inputs support that conclusion without factoring in consensus analyst targets. Result: Fair Value of $30.62 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on successful oncology execution and new product launches performing as expected. At the same time, high debt and any potential dividend cut could quickly challenge the bullish case. Find out about the key risks to this Pfizer narrative. Next Steps Conflicted about the mixed messages around Pfizer right now? Review the full picture so you can respond quickly and build your own view with 1 key reward and 4 important warning signs Looking for more investment ideas? If Pfizer has you thinking more broadly about where to put fresh capital, it is worth lining up a few other candidates before the next move presents itself.  Target dependable income opportunities by reviewing companies in the 12 dividend fortresses and see which payouts stand out to you. Hunt for quality at a reasonable price by scanning the 64 high quality undervalued stocks and compare which fundamentals best match your approach. Prioritize resilience by checking stocks in the 72 resilient stocks with low risk scores so you are not caught off guard when conditions change.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626390888","isCrawlerRequest":true}